| Drug ID: | Drug54 |
|---|---|
| Drug Name: | Ursodeoxycholic acid |
| CID: | 31401 |
| DrugBank ID: | DB01586 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00521950 |
| Molecular Formula: | C24H40O4 |
| Molecular Weight: | 392.6 g/mol |
| Isomeric SMILES: | C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C |
| Synonyms: | URSODEOXYCHOLIC ACID; ursodiol; 128-13-2; Actigall; UDCA; Ursodesoxycholic acid; Urso Forte; Litursol; Solutrat; Ursobilin |
| Phase 0: | 2 |
| Phase 1: | 30 |
| Phase 2: | 43 |
| Phase 3: | 44 |
| Phase 4: | 29 |
| Description: | Ursodeoxycholic acid is an epimer of chenodeoxycholic acid (DB06777). It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt492 | 31401 | Ursodiol | 9971 | NR1H4 | Homo sapiens (human) | Agonist | |
| dt493 | 31401 | Ursodiol | 1646 | AKR1C2 | Homo sapiens (human) | Inhibitor | |
| dt494 | 31401 | Ursodiol | 644 | BLVRA | Homo sapiens (human) | 37713619 | Activator |
| dt495 | 31401 | Ursodiol | 9962 | SLC23A2 | Homo sapiens (human) | 37713619 | Activator |
| dt496 | 31401 | Ursodiol | 9971 | NR1H4 | Homo sapiens (human) | 15935148 | Partial agonist |
| dt497 | 31401 | Ursodiol | 1576 | CYP3A4 | Homo sapiens (human) | Inducer | |
| dt498 | 31401 | Ursodiol | 64816 | CYP3A43 | Homo sapiens (human) | Inducer | |
| dt499 | 31401 | Ursodiol | 1577 | CYP3A5 | Homo sapiens (human) | Inducer | |
| dt500 | 31401 | Ursodiol | 1551 | CYP3A7 | Homo sapiens (human) | Inducer | |
| dt501 | 31401 | Ursodiol | 8647 | ABCB11 | Homo sapiens (human) | Substrate|Inhibitor|Inducer |
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03724175 | The Role of Secondary Bile Acids in Intestinal Inflammation | PHASE2|PHASE3 | RECRUITING | Stanford University | Ulcerative Colitis|Pouchitis | DRUG: ursodiol (ursodeoxycholic acid, UDCA) | Details |
| EUCTR2015-003310-24-SE | A Phase 3, Open-label, Randomized, Prospective Clinical Trial Evaluating the Efficacy of Stratified Treatment with Ursodeoxycholic Acid (UDCA) in Preventing Hepatobiliary and Colorectal Malignancy in Surveillance Patients with Primary Sclerosing Cholangitis (PSC) - UDCAPSCSURV | PHASE3 | Not Recruiting | Sahlgrenska Academy | Primary sclerosing cholangitis with or without co… | Trade Name: Ursofalk Product Name: Ursofalk Pharm… | Details |
| EUCTR2009-010921-38-NL | Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis:_A Double-blind, Randomized Placebo-controlled Pilot Study_ - CRC chemoprevention in UC | Not Available | Authorised | UMC Utrecht | Ulcerative Colitis and the risk of developing col… | Trade Name: Salofalk Pharmaceutical Form: Granule… | Details |
| NCT04114292 | TUDCA as a Therapy for Ulcerative Colitis (UC) | PHASE1 | UNKNOWN | Washington University School of Medicine | Ulcerative Colitis | DRUG: Tauroursoursodeoxycholic acid, brand name T… | Details |
| NL-OMON31889 | Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis:__ A Double-blind, Randomized Placebo-controlled Pilot Study__ - CRC chemoprevention in UC | Not Available | None | Universitair Medisch Centrum Utrecht | Inflammatory bowel disease ulcerative colitis;10… | There will be three groups: 1) This group will r… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Tauroursodeoxycholic Acid (TUDCA) Reduces ER Stress and Lessens Disease Activit…
PMID: 40236400
Year: 2025
Relationship Type:
Treatment
Score: 9.5
BACKGROUND AND AIMS: In inflammatory bowel disease, protein misfolding in the endoplasmic reticulum (ER) potentiates epithelial barrier dysfunction a…
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T(H)1…
PMID: 40032499
Year: 2025
Relationship Type:
Treatment
Score: 7.5
BACKGROUND: 24-Nor-ursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid for treating immune-mediated cholestatic liver diseases, such as p…
Gut-Derived Ursodeoxycholic Acid from Saponins of Quinoa Regulated Colitis via …
PMID: 39827465
Year: 2025
Relationship Type:
Mechanism
Score: 7.5
Alteration of the gut microbiota and its metabolites plays a key role in the development of inflammatory bowel disease (IBD). Here, we investigated t…
Therapeutic role of ursodeoxycholic acid in colitis-associated cancer via gut m…
PMID: 38556635
Year: 2023
Relationship Type:
Treatment
Score: 7.5
Inflammatory bowel disease (IBD) is a predisposing factor for colitis-associated cancer (CAC). The association between bile acids and the gut microbi…
[Therapeutic effect of ursodeoxycholic acid-berberine supramolecular nanopartic…
PMID: 37282934
Year: 2023
Relationship Type:
Treatment
Score: 7.5
Ulcerative colitis(UC) is a recurrent, intractable inflammatory bowel disease. Coptidis Rhizoma and Bovis Calculus, serving as heat-clearing and toxi…
A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn's Ileitis Follow…
PMID: 36273261
Year: 2022
Relationship Type:
Treatment
Score: 7.5
BACKGROUND There is a recognized association between inflammatory bowel disease (IBD) and hepatobiliary autoimmune disease, particularly primary scle…
Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis ma…
PMID: 33835051
Year: 2021
Relationship Type:
Treatment
Score: 7.5
BACKGROUND: We aimed to evaluate the therapeutic effect of additional ursodeoxycholic acid (UDCA) with mesalazine, compared to mesalazine alone in pa…
Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel dis…
PMID: 31509435
Year: 2019
Relationship Type:
Treatment
Score: 7.5
The secondary bile acid ursodeoxycholic acid (UDCA) has long been known to have medicinal properties. As the therapeutically active component of bear…
Tauroursodeoxycholic acid attenuates colitis-associated colon cancer by inhibit…
PMID: 30378164
Year: 2019
Relationship Type:
Treatment
Score: 7.5
BACKGROUND AND AIM: Inflammatory bowel diseases is associated with an increased risk for the development of colorectal cancer. However, the mechanism…
Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory con…
PMID: 28165466
Year: 2017
Relationship Type:
Treatment
Score: 7.3
Bile acids regulate the expression of intestinal bile acid transporters and are natural ligands for nuclear receptors controlling inflammation. Accum…
Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons
PMID: 23141896
Year: 2012
Relationship Type:
Association
Score: 7.1
Animal and human data suggest a relationship between bile acids, especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synt…
Ursodeoxycholic acid and chemoprevention of colorectal cancer
PMID: 20609543
Year: 2010
Relationship Type:
Association
Score: 7.1
Colorectal cancer is respectively the third and second most common cancer among men and women in France. Interest in chemoprevention for colorectal c…
Dihydroartemisinin-ursodeoxycholic acid conjugate is a potential treatment agen…
PMID: 36842236
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: A novel artemisinin derivative, dihydroartemisinin-ursodeoxycholic acid conjugate (4), was found to exhibit strong immunosuppressive acti…
Effectiveness of Ursodeoxycholic Acid in the Treatment of Primary Sclerosing Ch…
PMID: 33551380
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Primary sclerosing cholangitis is a rare disease with poor prognosis that potentially leads to liver cirrhosis and is often complicated by inflammato…
Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental …
PMID: 23246254
Year: 2013
Relationship Type:
Treatment
Score: 6.1
The denomination of inflammatory bowel disease comprises a group of chronic inflammatory diseases of the digestive tract, ulcerative colitis and Croh…
Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing…
PMID: 22528343
Year: 2012
Relationship Type:
Association
Score: 6.1
PURPOSE/AIM: Colon cancer risk is high in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). Ursodeoxycholic acid has be…
UDCA ameliorates inflammation driven EMT by inducing TGR5 dependent SOCS1 expre…
PMID: 39414916
Year: 2024
Relationship Type:
Treatment
Score: 5.5
Long-standing chronic inflammation of the digestive tract leads to Inflammatory Bowel Diseases (IBD), comprising Crohn's Disease (CD) and Ulcerative …